ERBB2 and breast carcinoma: Further antibody–drugconjugate (ADC) synthesis and stability assessment was undertakenby Shin et al.,106 utilizing the same approachoutlined by Kim et al., and a HER2-targeting antibody (overexpressionof human epidermal growth factor receptor 2, or HER2, is a markerof breast cancer).